BOLETÍN BIBLIOGRÁFICO
DE INMUNOTERAPIA
Artículo destacado – Octubre 2018
1
Las partículas “virus-like” aumentan la inmunogenicidad del alérgeno, haciéndolos adyuvantes prometedores.
Virus-Like Particles as Carrier Systems to Enhance Immunomodulation in Allergen Immunotherapy.
Anzaghe M, Schülke S, Scheurer S
Curr Allergy Asthma Rep. 2018 Oct 25;18(12):71. doi: 10.1007/s11882-018-0827-1.
PURPOSE OF REVIEW
Utilization of virus-like particles (VLPs) is considered to improve allergen-specific immunotherapy (AIT). AIT aims at the efficient uptake of the target allergen by antigen-presenting cells (APCs) subsequently inducing adaptive allergen-specific immune responses to induce tolerance. The purpose of this review is to describe the immune-modulating properties of VLPs per se and to summarize the application of VLPs as antigen carriers, preferably for Th2 cytokines or allergens, with and without simultaneous administration of adjuvants in order to modulate allergic immune responses.
RECENT FINDINGS
Currently, a broad variety of approaches considering the origin of the VLPs, the choice of the adjuvant and antigen, and the coupling of the antigen are under preclinical investigation. The data provide evidence that VLPs used as carrier for antigens/allergens strongly increase antigen immunogenicity, and might be suitable to prevent allergies. However, systematic studies in mice showing the immunological mechanism and data from clinical studies are scarce.